AT7867 dihydrochloride is an ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA, with IC50 values of 32 nM, 17 nM, 47 nM, 85 nM, and 20 nM, respectively; it exhibits potent anti-proliferative activity in various human cancer cell lines, particularly in MES-SA uterine, MDA-MB-468 and MCF-7 breast, and HCT116 and HT29 colon cancer cells (IC50 ranging from 0.9 to 3 μM); it is used in in vivo pharmacodynamic studies to inhibit phosphorylation of GSK3β and S6RP, key biomarkers of Akt pathway activity, in tumor xenograft models.